Cargando…
The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol
Statins are the first-line lipid-lowering therapy for reducing cardiovascular disease (CVD) risk. A plasma lipid ratio of two phospholipids, PI(36:2) and PC(18:0_20:4), was previously identified to explain 58% of the relative CVD risk reduction associated with pravastatin, independent of a change in...
Autores principales: | Schooneveldt, Yvette L., Giles, Corey, Keating, Michael F., Mellett, Natalie A., Jurrjens, Aaron W., Paul, Sudip, Calkin, Anna C., Meikle, Peter J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228384/ https://www.ncbi.nlm.nih.gov/pubmed/34070445 http://dx.doi.org/10.3390/metabo11060340 |
Ejemplares similares
-
Ether Lipids in Obesity: From Cells to Population Studies
por: Schooneveldt, Yvette L., et al.
Publicado: (2022) -
The potential of integrating human and mouse discovery platforms to advance our understanding of cardiometabolic diseases
por: Jurrjens, Aaron W, et al.
Publicado: (2023) -
The Effects of Long-Term Saturated Fat Enriched Diets on the Brain Lipidome
por: Giles, Corey, et al.
Publicado: (2016) -
Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study
por: Kaddurah-Daouk, Rima, et al.
Publicado: (2010) -
Lipidomic Profiling Identifies Serum Lipids Associated with Persistent Multisite Musculoskeletal Pain
por: Ma, Canchen, et al.
Publicado: (2022)